{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:49:27Z","timestamp":1790210967112,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.critrevonc.2008.10.011","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T12:17:50Z","timestamp":1228393070000},"page":"181-198","source":"Crossref","is-referenced-by-count":21,"title":["Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets"],"prefix":"10.1016","volume":"71","author":[{"given":"J.","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mart\u00ednez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perez-Manga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO;2-B","article-title":"Peripheral T-cell lymphoma","volume":"63","author":"Armitage","year":"1989","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.1989.7.12.1783","article-title":"Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma","volume":"7","author":"Armitage","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib5","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib6","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib7","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.critrevonc.2008.10.011_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.critrevonc.2008.10.011_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","article-title":"The biology of human lymphoid malignancies revealed by gene expression profiling","volume":"87","author":"Staudt","year":"2005","journal-title":"Adv Immunol"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib12","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"25","author":"Ballester","year":"2006","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.781","article-title":"Peripheral T-cell lymphoma gene expression profiles","volume":"24","author":"Martinez-Delgado","year":"2006","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0002-9440(10)63742-X","article-title":"Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations","volume":"164","author":"Zettl","year":"2004","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.humpath.2005.03.004","article-title":"Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas","volume":"36","author":"Thompson","year":"2005","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib18","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Martinez-Delgado","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0037-1963(03)00195-1","article-title":"Gene expression profiling in T-cell acute lymphoblastic leukemia","volume":"40","author":"Ferrando","year":"2003","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2008.10.011_bib21","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/1078-0432.CCR-04-0269","article-title":"Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes","volume":"10","author":"Martinez-Delgado","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00000478-200012000-00006","article-title":"Lennert's lymphoma: a variant of cytotoxic T-cell lymphoma?","volume":"24","author":"Yamashita","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"10.1016\/j.critrevonc.2008.10.011_bib24","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Cuadros","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-05-0146","article-title":"Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures","volume":"4","author":"Mahadevan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib26","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2006-06-028969","article-title":"Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes","volume":"109","author":"Lamant","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib27","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3747\/co.2007.132","article-title":"Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182\u2013185","volume":"14","author":"Buckstein","year":"2007","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2008.10.011_bib29","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/blood-2002-09-2908","article-title":"The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity","volume":"101","author":"Krenacs","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0037-1963(03)00132-X","article-title":"Classification of cytotoxic T-cell and natural killer cell lymphomas","volume":"40","author":"Jaffe","year":"2003","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1440-1827.2003.01479.x","article-title":"Phenotypic analysis of peripheral T\/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites","volume":"53","author":"Ichimura","year":"2003","journal-title":"Pathol Int"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib33","first-page":"605","article-title":"Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis","volume":"25","author":"Ohshima","year":"2004","journal-title":"Int J Oncol"},{"issue":"16","key":"10.1016\/j.critrevonc.2008.10.011_bib34","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/hupa.2002.32215","article-title":"CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas","volume":"33","author":"Dorfman","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2002-05-1352","article-title":"Th1, Th2 and activated T-cell marker, and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL","volume":"103","author":"Tsuchiya","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(99)00151-X","article-title":"Chromosome abnormalities in peripheral T-cell lymphoma","volume":"117","author":"Lepretre","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","article-title":"Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma","volume":"141","author":"Nelson","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/path.945","article-title":"p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome","volume":"195","author":"Pescarmona","year":"2001","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V73.3.747.747","article-title":"Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation","volume":"73","author":"Dalton","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.1346","article-title":"BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood.V87.3.1045.bloodjournal8731045","article-title":"Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO","volume":"87","author":"d\u2019Amore","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib44","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2741\/2844","article-title":"Role of CD26\/dipeptidyl peptidase IV in human T cell activation and function","volume":"13","author":"Ohnuma","year":"2008","journal-title":"Front Biosci"},{"issue":"6 Suppl 2","key":"10.1016\/j.critrevonc.2008.10.011_bib45","first-page":"17","article-title":"CD26 in T-cell lymphomas: a potential clinical role?","volume":"14","author":"Verstovsek","year":"2000","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0046-8177(94)90098-1","article-title":"CD26\/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas","volume":"25","author":"Carbone","year":"1994","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib47","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood.V86.12.4617.bloodjournal86124617","article-title":"The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas\/leukemias","volume":"86","author":"Carbone","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib48","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-0755-03","article-title":"CD26 expression correlates with a reduced sensitivity to 2\u2032-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia\/lymphomas","volume":"10","author":"Aldinucci","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib49","first-page":"1513","article-title":"Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes","volume":"10","author":"Dang","year":"2003","journal-title":"Oncol Rep"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib50","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2007-08-108654","article-title":"PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor","volume":"111","author":"Zhao","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2008.10.011_bib51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2008.10.011_bib53","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.critrevonc.2008.10.011_bib54","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodriguez","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib55","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib56","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib57","first-page":"v131","article-title":"ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T-cell lymphoma: a GELA phase II trial of feasability and efficacy","volume":"16","author":"Bouabdallah","year":"2005","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.critrevonc.2008.10.011_bib58","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.thj.6200359","article-title":"Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study","volume":"5","author":"Reimer","year":"2004","journal-title":"Hematol J"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib60","first-page":"641a","article-title":"Front-line consolidation with autologous stem cell transplantation in patients woth nodal agrressive peripheral T cell lymphoma (PTCL). A prospective study of the GEL-TAMO","volume":"108","author":"Rodriguez","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib61","first-page":"v15","article-title":"High-dose therapy and autologous stem cell transplant as first line treatment in peripheral T-cell lymphomas","volume":"16","author":"D\u2019Amore","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2008.10.011_bib62","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib63","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood.V106.11.2077.2077","article-title":"Intensive chemotherapy (High-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation (ASCT) in previously untreated patients with peripheral T-cell lymphoma (PTCL). Results of a prospective phase II study from the GELCAB","volume":"106","author":"Lopez-Guillermo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib65","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V106.11.2074.2074","article-title":"Autologous stem cell transplantation as first-line therapy in peripheral T-cell lymphomas. A prospective multicenter study","volume":"106","author":"Reimer","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib66","doi-asserted-by":"crossref","first-page":"401a","DOI":"10.1182\/blood.V108.11.401.401","article-title":"Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T cell lymphoma (PTCL)\u2014a phase II Study of the Nordic Lymphoma Group (NLG)","volume":"108","author":"D\u2019Amore","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib67","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib68","first-page":"1372","article-title":"High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2008.10.011_bib69","first-page":"P668","article-title":"High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in patients with primary refractory aggressive non-Hodgkin's lymphoma","volume":"27","author":"Rodriguez","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.critrevonc.2008.10.011_bib70","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib72","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib73","first-page":"646a","article-title":"Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)","volume":"100","author":"Kewalramani","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib74","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib75","first-page":"v56","article-title":"Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL): the Spanish Lymphoma Cooperative Group (GEL-TAMO) experience","volume":"16","author":"Rodriguez","year":"2005","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib76","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib77","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V87.4.1243.bloodjournal8741243","article-title":"Primary systemic CD30 (Ki-1) positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with F-MACHOP regimen (+\/\u2212 radiotherapy) and autologous bone marrow transplantation","volume":"87","author":"Fannin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib78","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","article-title":"Autologous stem cell transplantation for anaplastic large cell lymphoma: results of a prospective trial","volume":"109","author":"Deconinck","year":"2000","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.critrevonc.2008.10.011_bib79","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V90.9.3727","article-title":"Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome","volume":"90","author":"Tilly","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib80","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib81","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2559.2003.01726.x","article-title":"ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified","volume":"43","author":"Ten Berge","year":"2003","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.1331","article-title":"ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects\u2014a review","volume":"200","author":"Ten Berge","year":"2003","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.critrevonc.2008.10.011_bib83","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib84","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib85","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/10428190310001597955","article-title":"Stem cell transplantation for peripheral T-cell lymphomas","volume":"45","author":"Jantunen","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib86","first-page":"43a","article-title":"Prospective evaluation of a novel treatment protocol for intestinal T cell NHL","volume":"13","author":"Lennard","year":"2002","journal-title":"Ann Oncol"},{"issue":"5 Suppl 1","key":"10.1016\/j.critrevonc.2008.10.011_bib87","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jaad.2004.05.042","article-title":"High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma","volume":"52","author":"Alaibac","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1034\/j.1600-0609.2003.00058.x","article-title":"Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation","volume":"70","author":"Mukai","year":"2003","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib89","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib90","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib91","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(05)70213-8","article-title":"Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified","volume":"6","author":"Piccaluga","year":"2005","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.annonc.a059281","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group","volume":"6","author":"Siegert","year":"1995","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib93","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1008275208592","article-title":"Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine","volume":"8","author":"Advani","year":"1997","journal-title":"Ann Oncol"},{"issue":"8 Suppl","key":"10.1016\/j.critrevonc.2008.10.011_bib94","first-page":"ECR44","article-title":"Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone","volume":"91","author":"Ramasamy","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib95","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002770050244","article-title":"Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine","volume":"73","author":"Sallah","year":"1996","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10428190210190","article-title":"Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports","volume":"43","author":"Strupp","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib97","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.mph.0000187431.37369.f5","article-title":"Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature","volume":"27","author":"Domm","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib98","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705272","article-title":"Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation","volume":"37","author":"Sakai","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib99","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1080\/10428190600783619","article-title":"Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor","volume":"47","author":"Ichii","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib100","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.critrevonc.2008.10.011_bib101","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1749-6632.2001.tb03724.x","article-title":"Therapy of T cell lymphomas with pentostatin","volume":"941","author":"Kurzrock","year":"2001","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib104","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.cco.0000245326.65152.af","article-title":"Clofarabine and nelarabine: two new purine nucleoside analogs","volume":"18","author":"Gandhi","year":"2006","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2008.10.011_bib106","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"Pharmacokinetics of nelarabine and 9-beta-d-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.critrevonc.2008.10.011_bib107","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib108","first-page":"369a","article-title":"Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy","volume":"102","author":"Goy","year":"2003","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2008.10.011_bib109","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.critrevonc.2008.10.011_bib110","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.critrevonc.2008.10.011_bib112","first-page":"1487","article-title":"Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro","volume":"57","author":"Li","year":"1997","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.critrevonc.2008.10.011_bib113","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"issue":"7914","key":"10.1016\/j.critrevonc.2008.10.011_bib114","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2008.10.011_bib115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2014a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib116","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1567-5769(03)00044-4","article-title":"Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2\u2032-deoxyguanosine in primates","volume":"3","author":"Kilpatrick","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib117","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O\u2019Connor","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00255903","article-title":"New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties","volume":"12","author":"Sirotnak","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"10.1016\/j.critrevonc.2008.10.011_bib119","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","article-title":"Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies","volume":"23","author":"Bhalla","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer","volume":"184","author":"Cress","year":"2000","journal-title":"J Cell Physiol"},{"issue":"15","key":"10.1016\/j.critrevonc.2008.10.011_bib121","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib122","first-page":"3061a","article-title":"Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228","volume":"23","author":"Piekarz","year":"2005","journal-title":"Proc ASCO"},{"issue":"12","key":"10.1016\/j.critrevonc.2008.10.011_bib123","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2008.10.011_bib124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.critrevonc.2008.10.011_bib125","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib126","first-page":"42","article-title":"New drugs for peripheral T-cell lymphomas","volume":"2","author":"Cheson","year":"2006","journal-title":"Haematol Rep"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib127","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0609.2004.00362.x","article-title":"Single-agent thalidomide induces response in T-cell lymphoma","volume":"74","author":"Damaj","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2008.10.011_bib129","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2008.10.011_bib130","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib131","doi-asserted-by":"crossref","first-page":"769a","DOI":"10.1182\/blood.V108.11.2721.2721","article-title":"A phase II immunochemotherapy study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"108","author":"Weidmann","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2008.10.011_bib132","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2008.10.011_bib133","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib134","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib135","first-page":"399","article-title":"Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2008.10.011_bib136","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.21851","article-title":"Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia","volume":"106","author":"Frankel","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2008.10.011_bib137","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2008.10.011_bib138","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib139","doi-asserted-by":"crossref","first-page":"2712a","DOI":"10.1182\/blood.V108.11.2712.2712","article-title":"Efficacy and safety of Denileukin Diftitox (Ontak\u00ae) in the treatment of cutaneous T-cell lymphoma (CTCL) according to CD25 status","volume":"108","author":"Foss","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib140","doi-asserted-by":"crossref","first-page":"6601a","DOI":"10.1200\/jco.2005.23.16_suppl.6601","article-title":"Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)","volume":"23","author":"Forero","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib141","doi-asserted-by":"crossref","first-page":"3431a","DOI":"10.1182\/blood.V110.11.3431.3431","article-title":"Final analysis of phase II study of CHOP\/CHOEP-14 followed by consolidation with Alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1)","volume":"110","author":"Binder","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2008.10.011_bib142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ncponc0078","article-title":"Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?","volume":"2","author":"Rodriguez","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"issue":"2 Suppl 5","key":"10.1016\/j.critrevonc.2008.10.011_bib143","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/j.seminoncol.2006.01.029","article-title":"The role of alemtuzumab in the management of T-cell malignancies","volume":"33","author":"Dearden","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib144","doi-asserted-by":"crossref","first-page":"5431a","DOI":"10.1182\/blood.V108.11.5431.5431","article-title":"Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation","volume":"108","author":"Reimer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib145","doi-asserted-by":"crossref","first-page":"401a","DOI":"10.1182\/blood.V108.11.401.401","article-title":"Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)\u2014a phase II study of the Nordic Lymphoma Group (NLG)","volume":"108","author":"d\u2019Amore","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.011_bib146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808002771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808002771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T20:35:19Z","timestamp":1589315719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842808002771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1040842808002771"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2008.10.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}